Eczema and New Depression or Anxiety: What a Three-Million-Adult Cohort Actually Measured
Educational information from Dr. Arsy Editorial, checked November 9, 2026. This article does not replace individual medical care. The cited researchers and organizations do not endorse #003.
If eczema is disrupting work, friendships or a regular walk, an important question is whether research measures temporary distress, questionnaire symptoms or newly recorded mental-health diagnoses. Those outcomes are different. A large UK study published online in 2019 examined new clinician-recorded depression and anxiety, rather than assuming every difficult eczema week represents a psychiatric disorder.
Who entered the study—and who entered each analysis?
The matched primary-care cohort initially identified 526,808 adults with treated atopic eczema and 2,569,030 matched adults without it, using records from 1998–2016. The investigators then excluded relevant pre-existing psychiatric diagnoses. That left 2,467,791 participants for the depression outcome and 2,650,629 for anxiety. The initial three-million-person population was therefore not the denominator for every result.
Median follow-up was approximately 4.7 years in those with eczema and 4.2 years in comparators. These are historical UK records, not a trial of a moisturizer or a prediction tool for an individual adult today.
Read the model and the interval together
| Outcome | Main adjusted hazard ratio | Additional mediator adjustment |
|---|---|---|
| New depression | 1.14; 99% CI 1.12–1.16 | 1.10; 99% CI 1.10–1.12 |
| New anxiety | 1.17; 99% CI 1.14–1.19 | 1.12; 99% CI 1.10–1.15 |
The main model accounted for age, sex, practice, calendar period and deprivation. The additional model included BMI, smoking, harmful alcohol use and high-dose glucocorticoids, which the researchers treated as possible mediating factors. The columns answer related but different questions. The paper used 99% confidence intervals; silently relabeling them 95% would misreport the study.
In the authors’ separate absolute-rate calculations, the estimated excess was 160 depression diagnoses and 144 anxiety diagnoses per 100,000 person-years. These modeled differences are not 14 or 17 extra diagnoses per 100 people. Nor do observational “attributable” calculations establish that eczema alone caused those events.
Severity was not a simple staircase for both outcomes
The depression association increased from mild to moderate to severe eczema: main adjusted hazard ratios 1.10, 1.19 and 1.26. Anxiety estimates were 1.14, 1.21 and 1.15. The anxiety pattern did not increase steadily with severity. Treatment and referral records defined severity, could miss untreated mild eczema, and could retain a severe classification after symptoms improved. Missing lifestyle information and differences in medical contact also complicate interpretation.
Turn the finding into a useful appointment
Bring changes in enjoyment, worry, sleep, concentration and daily functioning to your clinician alongside skin symptoms. NIMH guidance explains that persistent symptoms deserve assessment; a diagnosis considers the pattern, duration and effect on life. You do not have to wait until eczema looks severe to discuss mental health. Seek urgent help if you feel unsafe.
Our emotional-wellbeing guide offers broader support; the nurses’ survey addresses a different, cross-sectional question. For practical context, read about eczema and sleep and a mindfulness intervention trial. None establishes that cosmetic hydration treats depression or anxiety.
Dr. Arsy Moisturizer #003 can support hydration, the moisture barrier and ordinary dry-skin comfort. It is not a treatment for eczema, anxiety or depression, and it should not replace either dermatologic or mental-health care.